Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Ovid Therapeutics Inc
OVID
Healthcare
Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other...
neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:OVID)
New Post
View:
Posts & Comments
Threaded Posts
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Sep 25, 2019 2:49pm
still holding this stock
it would be nice to have $5 to $6 per share for me,so glta shareholders.
(83)
•••
Biomed4077
X
View Profile
View Bullboard History
Post by
Biomed4077
on Sep 24, 2019 9:40pm
Get ready for $ 12 US
https://seekingalpha.com/news/3501176-ovid-7-percent-positive-soticlestat-data
Pampa Metals Intersects 448 m @ 0.42% Cu, 0.46 g/t Au including 126m @ 0.66% Cu, 0.74 g/t Au
posted May 07, 2024 9:00am by
Pampa Metals Corp.
-
|
"Following on from the exceptional porphyry copper-gold intersections reported in the first hole of our maiden drill campaign at Piuquenes we are very pleased to report further long intervals of strong primary copper mineralization in the second hole. Our initial drilling continues to extend the depth and lateral extensions of mineralization at Piuquenes Central and has confirmed a highly mineralized multi-phase porphyry system ...read more
(83)
•••
Biomed4077
X
View Profile
View Bullboard History
Post by
Biomed4077
on Sep 24, 2019 9:38pm
Get ready for $12 US
https://www.empr.com/home/mpr-first-report/aan-2019-coverage/ov101-gaboxadol-beneficial-in-adolescents-and-adults-with-angelman-syndrome/
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Apr 26, 2019 2:03pm
still cheap at these prices
will add more next week,probably at the end of the month.
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Apr 23, 2019 10:49am
it's a buy today for me
at these low prices,so glta.
(0)
•••
Tiffany
X
View Profile
View Bullboard History
Post by
Tiffany
on Apr 23, 2019 10:36am
Lots of things going on un the next few weeks
cheers
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share